Compare National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares vs Revolution Medicines Inc. Common Stock — how do they compare? National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $78.5 (market cap $78.25B), while Revolution Medicines Inc. Common Stock trades at $193.15 (market cap $40.39B). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is the larger of the two by market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays a 4.14% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals.
| NGG | RVMD | |
|---|---|---|
Market Cap | $78.25B | $40.39B |
Volume | 1,070,031 | 2,941,009 |
Sector | Utilities | Health |
52-Week High | $93.93 | $221.15 |
52-Week Low | $73.54 | $49.56 |
Enterprise Value | $136.28B | $37.09B |
Dividend Yield | 4.14% | — |
Typical Hold Time | — | 2 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
Revolution Medicines (RVMD) trades at $188.44, down 2.84% on the day, amid a bearish technical signal. The company reported no revenue in 2025, with a net loss of $1.13 billion, and has missed earnings expectations for three consecutive quarters. However, recent positive developments include the start of a Phase 3 trial for RASONQUE in pancreatic cancer and FDA Breakthrough Therapy Designation, fueling analyst optimism.
The outlook balances high-risk, high-reward potential. Strong analyst support (91.67% buy ratings) and a $253.35 consensus price target suggest significant upside, driven by the promising oncology pipeline. Key risks include substantial cash burn, lack of current revenue, and clinical trial execution uncertainties, making the stock suitable for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares
National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
